Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 3/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970352 | 0.84 | HRH3 (0.44) | PIM1 | |
| SCHEMBL973136 | 0.78 | MAOB (0.49) | HCAR3APPMAOB | |
| SCHEMBL4873803 | 0.70 | MAP4K4 (0.38) | PIM1HCAR3ALDH1A1KDM4ETLR7 | |
| SCHEMBL2892169 | 0.69 | RAB9A (0.39) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL17364403 | 0.66 | CHRNB2 (0.51) | PIM1HCAR3APPPDE5AALDH1A1 | |
| SCHEMBL969519 | 0.65 | PLAU (0.36) | — | |
| SCHEMBL971212 | 0.65 | — | — | |
| SCHEMBL4764029 | 0.65 | — | — | |
| SCHEMBL7511217 | 0.65 | NCF1 (0.60) | APPPDE5AELANEKDM4ETLR8 | |
| SCHEMBL4636102 | 0.65 | KDM6B (0.36) | HCAR3PDE5AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | PIM1 3833/4885HCAR3 30/4885APP 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.